Ventyx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	52.55	64.82	70.79	0.24	0.31
Short-Term Investments	200.64	253.12	187.79	0	0
Cash & Cash Equivalents	253.2	317.94	258.58	0.24	0.31
Cash Growth	-20.36%	22.96%	105873.77%	-21.04%	-
Other Current Assets	11.15	12.75	4.44	0	0.04
Total Current Assets	264.35	330.69	263.02	0.25	0.35
Property, Plant & Equipment	12.27	1.94	0.25	0	0
Long-Term Investments	0	38.67	28.15	0	0
Other Long-Term Assets	1.08	0.1	0.06	0	0
Total Long-Term Assets	13.35	40.71	28.46	0	0
Total Assets	277.69	371.4	291.48	0.25	0.35
Accounts Payable	5.76	6.43	4.66	1.1	0.36
Current Debt	1	0.41	0	0	0
Other Current Liabilities	15.51	9.51	7.62	0.3	0.27
Total Current Liabilities	22.27	16.36	12.28	1.4	0.63
Long-Term Debt	11.51	1.15	0	12.65	3.85
Other Long-Term Liabilities	0	0	0	16.85	0
Total Long-Term Liabilities	11.51	1.15	0	29.5	3.85
Total Liabilities	33.77	17.51	12.28	30.9	4.48
Total Debt	12.51	1.56	0	12.65	3.85
Debt Growth	702.70%	-	-	228.84%	-
Retained Earnings	-419.19	-226.23	-117.8	-32.5	-4.33
Comprehensive Income	-0.05	-1.12	-0.06	0	0
Shareholders' Equity	243.92	353.9	279.2	-30.65	-4.13
Net Cash / Debt	240.69	316.38	258.58	-12.4	-3.54
Net Cash / Debt Growth	-23.92%	22.36%	-	-	-
Net Cash Per Share	4.11	6.03	20.16	-6.24	-2.13
Working Capital	242.08	314.33	250.74	-1.16	-0.28
Book Value Per Share	4.17	6.75	21.77	-15.41	-2.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).